Prevalence of Dissociative Identity Disorder in At-risk Outpatient Groups Reporting Childhood Trauma. (IDENTITY)

The investigators will study the prevalence of dissociative identity disorder (DID) in three populations at risk in cases of childhood psychotrauma : patients with a diagnosis of borderline personality, patients with a diagnosis of functional dissociative crises (FDC) and patients with early psychosis.

The investigators will also study the prevalence of other dissociative disorders and the frequency of complex post-traumatic stress disorder.

The investigators will also look for correlations between the type of maltreatment in childhood, the age of onset of trauma and the type of diagnosis of dissociative disorders.

The investigators hope to include 150 borderline patients, 150 FDC patients and 50 early psychosis patients.

Data collection will be done via a psychometric administration of 7 self-completion questionnaires as well as the completion of the SCID-D semi-structured interview.

Study Overview

• Status: Recruiting
• Conditions: Dissociative Disorder
• Intervention / Treatment: Diagnostic test: psychometric assessment; Diagnostic test: semi-structured clinical interview

• Study Type: Interventional
• Enrollment (Estimated): 350
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Tatiana DABROWSKI; Phone Number: +33383925349; Email: unic@cpn-laxou.com
• Study Contact Backup: Name: Lori PETROCELLI; Phone Number: +33383852377; Email: petrocelli.psy@gmail.com

Study Locations

• France
  • Nancy, France
    • Not yet recruiting
    • Centre Psychothérapique de Nancy - CLIP
    • Principal Investigator: Vincent LAPRÉVOTE
    • Contact: Vincent LAPRÉVOTE; Email: vincent.laprevote@cpn-laxou.com
    • Sub-Investigator: Lori PETROCELLI
  • Nancy, France
    • Recruiting
    • Centre Psychothérapique de Nancy - CMP Jacquard et Des Près
    • Sub-Investigator: Lori PETROCELLI
    • Contact: Coraline HINGRAY; Email: coraline.hingray@cpn-laxou.com
    • Principal Investigator: Coraline HINGRAY
  • Nancy, France
    • Recruiting
    • CHRU Nancy - Neurology department
    • Sub-Investigator: Lori PETROCELLI
    • Contact: Coraline HINGRAY; Email: coraline.hingray@cpn-laxou.com
    • Principal Investigator: Coraline HINGRAY
    • Sub-Investigator: Alexis TARRADA
    • Sub-Investigator: Séverine CONRADI

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

I - Inclusion Criteria:

I-1: For all groups:

• Male or female
• Age > or = 18
• Enrolled in or benefiting from a social security scheme
• Patient fluent in French
• Patient willing to undergo a psychological evaluation between 1h30 and 3h30
• Patient with a known history of psychotrauma in childhood before the age of 18 (sexual abuse, mistreatment, school harassment, natural disasters, attacks, etc.).
• Patient having received and understood complete information on the organization of the research and having given written free and informed consent prior to participation in the study.

I-2 : Patients in the borderline group

• Patients with main diagnosis of emotionally labile personality
• Patients with at least one psychiatric hospitalization in the last 3 years

I-3 : Patients in the early psychosis group

Patient with a diagnosis of mental state at risk of psychosis according to the criteria defined by CAARMS (Comprehensive Assessment of At Risk Mental State) OR Patients diagnosed with a first psychotic episode on an outpatient basis or following a hospital stay

I-4 : Patients in the functional dissociative crises group

Patients diagnosed with functional dissociative crises by a specialized epileptologist

II- Non-inclusion criteria

• Impairment of the subject making it difficult or not impossible to participate in the trial or to understand the information provided to him/her
• Patients with specific difficulties in understanding SCID-D questions
• Psychiatric condition requiring hospitalization
• Patients with symptoms of recent toxic consumption (alcohol, cannabis, other ...) disrupting assessment responses
• Patient taking part in a pharmacological study involving a pro-dissociative molecule of the psychedelic type
• Pregnant, parturient or nursing mothers
• Person deprived of liberty by judicial or administrative decision
• Person in a life-threatening emergency
• An adult under legal protection (guardianship, curatorship, safeguard of justice)
• Person unable to give consent and not subject to a legal protection measure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Early psychosis; Early psychosis patients : mental state at risk for psychosis and first psychotic episode	Diagnostic test: psychometric assessment; Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.; Diagnostic test: semi-structured clinical interview; Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
Other: Borderline; Borderline patients	Diagnostic test: psychometric assessment; Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.; Diagnostic test: semi-structured clinical interview; Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
Other: Functional Dissociative Crises (FDC); FDC patients	Diagnostic test: psychometric assessment; Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.; Diagnostic test: semi-structured clinical interview; Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders / DSM = Diagnostic and Statistical Manual of Mental Disorders / ICD = International Classification of Diseases	assesses the dissociative identity disorder	Inclusion visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders	assesses the 4 others domains of dissociative disorders	Inclusion visit
CTQ-28 : Childhood Trauma Questionnaire	assesses history of childhood abuse and childhood trauma. For the CTQ-28, the overall score is not really relevant, but rather the scores for each type of abuse. For each type of maltreatment, there are differences in severity, ranging from "none" to "severe", with threshold scores for each level. In fact, there is no real overall minimum or maximum score.	Inclusion visit
life events inventory DSM-5	assesses history of potentially traumatic life events. There is no numerical score, it's simply an inventory of potentially traumatic life events.	Inclusion visit
PCL-5 : Posttraumatic stress disorder CheckList-5	assess the Post Traumatic Stress Disorder. For the PCL-5, the threshold score is 33, so a score of 33 or more suggests the presence of PTSD : the higher the score, the greater the symptomatology. The score is not a value used for interpretation purposes. The investigators use only threshold scores, or diagnostic criteria.	Inclusion visit
ITQ : International Trauma Questionnaire	assesses simple and complex post-traumatic stress syndrome. For the ITQ, there is no real numerical score; the diagnosis of PTSD or complex PTSD is made on the basis of the diagnostic criteria met. Scores are not given with numbers, but only with the presence or absence of simple or complex PTSD. There is no minimum or maximum score.	Inclusion visit
SDQ-20 : Somatoform Dissociative questionnaire	assess somatoform dissociation. For the SDQ-20, the threshold score is 28, and there are no levels of severity: the higher the score, the more severe the somatoform dissociative disorders. However, the score should be treated with caution, as if the symptoms reported by the patient are explained by a medical cause, we cannot conclude that dissociative disorders are present despite the score.	Inclusion visit
DIS-Q : Dissociation Questionnaire	assess the dissociative disorders. For the DIS-Q, the threshold score is 2.5. The score is not a value used for interpretation purposes. The investigators use only threshold scores, or diagnostic criteria.	Inclusion visit
DES : Dissociative Experience Scale	assess the dissociative disorder. For the DES, there is a threshold score of 15, and the higher the score, the more severe the dissociative disorders, but there are no multiple levels of severity. The score is not a value used for interpretation purposes. The investigators use only threshold scores, or diagnostic criteria.	Inclusion visit

Collaborators and Investigators

• Sponsor: Centre Psychothérapique de Nancy
• Investigators: Principal Investigator: Coraline HINGRAY, Centre Psychothérapique de Nancy

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2024
• Primary Completion (Estimated): August 18, 2026
• Study Completion (Estimated): August 18, 2026

Study Registration Dates

• First Submitted: March 19, 2024
• First Submitted That Met QC Criteria: March 19, 2024
• First Posted (Actual): March 26, 2024

Study Record Updates

• Last Update Posted (Actual): April 24, 2026
• Last Update Submitted That Met QC Criteria: April 21, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Psychosis; Borderline; Complex PTSD; Dissociative Identity Disorder (DID); Functional Dissociative Crises (FDC)
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Psychotic Disorders; Dissociative Disorders; Dissociative Identity Disorder
• Other Study ID Numbers: 2023-A02442-43; RIPH 2023-02 (Registry Identifier: sponsor's internal reference)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No